{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:02:42Z","timestamp":1788220962223,"version":"build-2803163510"},"reference-count":15,"publisher":"SAGE Publications","issue":"2","license":[{"start":{"date-parts":[[2019,6,19]],"date-time":"2019-06-19T00:00:00Z","timestamp":1560902400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["J Oncol Pharm Pract"],"published-print":{"date-parts":[[2020,3]]},"abstract":"\n Introduction<\/jats:title>\n Ibrutinib is an oral inhibitor of Bruton\u2019s tyrosine kinase that is used for a variety of B cell hematological malignancies. Skin and subcutaneous tissue manifestations have been reported and were witnessed in up to 32% of the patients on ibrutinib. The mechanism in which ibrutinib can cause skin toxicities has been thought due to the inhibition of epidermal growth factor; c-Kit and platelet-derived growth factor receptor). Here, we report a case of an elderly chronic lymphocytic leukemia patient who developed multiple inflamed lesions and lower limb cellulitis in 100 days after initiating ibrutinib therapy.<\/jats:p>\n <\/jats:sec>\n \n Case report<\/jats:title>\n A 68-year-old male patient with relapsed chronic lymphocytic leukemia was started on ibrutinib 420\u2009mg orally daily following multiple lines of therapy. Three months following ibrutinib, the patient developed multiple hyper pigmented lesions over both forearms then over both thighs; buttocks and lower limbs. The lesions were labeled as ecthyma and cellulitis that started as papules, which progressed to pustules.<\/jats:p>\n <\/jats:sec>\n \n Management and outcomes<\/jats:title>\n The patient required admission in which he received prolonged course of antibiotics. Biopsy from the wound showed soft tissue fragment infiltrated by acute and chronic inflammatory cells with necrosis; rare foreign body giant cells and granulation tissue formation; suggestive of abscess. Subsequently, ibrutinib was stopped permanently.<\/jats:p>\n <\/jats:sec>\n \n Discussion<\/jats:title>\n This is the first case description of an ibrutinib-associated sever skin toxicity in Qatar. The provided information regarding the clinical descriptions of toxicity profiles in general and skin-based in particular is valuable information for daily clinical practice, especially when selecting the optimum first-line treatment for the patient.<\/jats:p>\n <\/jats:sec>","DOI":"10.1177\/1078155219856422","type":"journal-article","created":{"date-parts":[[2019,6,19]],"date-time":"2019-06-19T13:20:30Z","timestamp":1560950430000},"page":"487-491","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":18,"title":["Ibrutinib-associated sever skin toxicity: A case of multiple inflamed skin lesions and cellulitis in a 68-year-old male patient with relapsed chronic lymphocytic leukemia \u2013 Case report and literature review"],"prefix":"10.1177","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1392-8831","authenticated-orcid":false,"given":"R","family":"Ghasoub","sequence":"first","affiliation":[{"name":"National Center for Cancer Care and Research, Hamad Medical Corporation (HMC), Doha, Qatar"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A","family":"Albattah","sequence":"additional","affiliation":[{"name":"National Center for Cancer Care and Research, Hamad Medical Corporation (HMC), Doha, Qatar"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0017-4401","authenticated-orcid":false,"given":"S","family":"Elazzazy","sequence":"additional","affiliation":[{"name":"National Center for Cancer Care and Research, Hamad Medical Corporation (HMC), Doha, Qatar"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R","family":"Alokka","sequence":"additional","affiliation":[{"name":"National Center for Cancer Care and Research, Hamad Medical Corporation (HMC), Doha, Qatar"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A","family":"Nemir","sequence":"additional","affiliation":[{"name":"College of Pharmacy, Qatar University, Doha, Qatar"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I","family":"Alhijji","sequence":"additional","affiliation":[{"name":"National Center for Cancer Care and Research, Hamad Medical Corporation (HMC), Doha, Qatar"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R","family":"Taha","sequence":"additional","affiliation":[{"name":"National Center for Cancer Care and Research, Hamad Medical Corporation (HMC), Doha, Qatar"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2019,6,19]]},"reference":[{"key":"bibr1-1078155219856422","unstructured":"U.S. Food and Drug Administration. Ibrutinib (Imbruvica), https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2018\/210563Orig1s000,210563Orig2s000TOC.cfm (accessed 15 February, 2019)."},{"key":"bibr2-1078155219856422","unstructured":"Ibrutinib drug, https:\/\/online.lexi.com\/lco\/action\/search?q=ibrutinib&t=name&va=ibrutinib (accessed 14 February, 2019)."},{"key":"bibr3-1078155219856422","unstructured":"Imbruvica (ibrutinib) (product monograph)\n . Toronto, Ontario, Canada: Janssen Inc., 2018."},{"key":"bibr4-1078155219856422","doi-asserted-by":"publisher","DOI":"10.1097\/DAD.0000000000000441"},{"key":"bibr5-1078155219856422","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.23775"},{"key":"bibr6-1078155219856422","doi-asserted-by":"publisher","DOI":"10.1007\/s12185-015-1900-3"},{"key":"bibr7-1078155219856422","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1215637"},{"key":"bibr8-1078155219856422","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(13)70513-8"},{"key":"bibr9-1078155219856422","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1306220"},{"key":"bibr10-1078155219856422","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.14302"},{"key":"bibr11-1078155219856422","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.1981.154"},{"key":"bibr12-1078155219856422","first-page":"1","volume":"2","author":"Baby AP","year":"2017","journal-title":"Skin Dis Skin Care"},{"key":"bibr13-1078155219856422","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdcr.2017.06.035"},{"key":"bibr14-1078155219856422","doi-asserted-by":"publisher","DOI":"10.4081\/dr.2017.6976"},{"key":"bibr15-1078155219856422","doi-asserted-by":"publisher","DOI":"10.1097\/DAD.0000000000000862"}],"container-title":["Journal of Oncology Pharmacy Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1078155219856422","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/1078155219856422","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1078155219856422","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T02:21:17Z","timestamp":1777688477000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/1078155219856422"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,6,19]]},"references-count":15,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2020,3]]}},"alternative-id":["10.1177\/1078155219856422"],"URL":"https:\/\/doi.org\/10.1177\/1078155219856422","relation":{},"ISSN":["1078-1552","1477-092X"],"issn-type":[{"value":"1078-1552","type":"print"},{"value":"1477-092X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,6,19]]}}}